OriA-631-B

N/A

Report date: 2023/11/07 14:49:27

First In Class

Base Information

Drug NameOriA-631-B

Drug Alias NameOriA631-BOriA-631-B

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Programmed death-ligand 1Anti-Ectonucleoside triphosphate diphosphohydrolase 1

TargetsProgrammed death-ligand 1Ectonucleoside triphosphate diphosphohydrolase 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesOriCell Therapeutics Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesOriCell Therapeutics Co Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A